CD8A and acute myeloid leukemia: No HLA class I-restricted TCRs for DNMT3A neoantigens have been identified to date, but we previously isolated an HLA-A*02:01-restricted TCR for a NPM1 neoantigen, which upon transfer to CD8 T cells effectively targets AML in vitro and in vivo (15).